2Seventy Bio

2seventy Bio, Inc. operates as cell and gene therapy company. It is focused on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

2Seventy Bio reports solid Q2 revenue, navigates competitive challenges

2Seventy Bio's Q2 2023 performance reflects strong revenue driven by ABECMA, with a focus on innovation and patient care. The company faces challenges from competitive dynamics and FDA clinical holds but is strategically positioned to capitalize on opportunities in the oncology space.

2Seventy Bio addresses challenges, highlights ABECMA support at Q3 call

2Seventy Bio navigated a challenging quarter with a focus on ABECMA support and organizational reshaping.
Key presentations at ASH showcased positive outcomes for ABECMA, while concerns around growth and profitability were addressed.
Management's commitment to stakeholders and strategic partnerships position the company for future growth and success.

2Seventy Bio reports robust Q4 earnings, eyes growth opportunities

2Seventy Bio's Q4 2023 earnings call highlighted strong financial performance, cost-saving initiatives, and confidence in Abecma's market potential.
While facing competition challenges and operational considerations, the company remains focused on growth, innovation, and financial sustainability.
Strategic partnerships, upcoming regulatory milestones, and a clear roadmap to breakeven underscore 2Seventy Bio's commitment to long-term success.

2Seventy Bio focuses on Abecma growth post realignment

2Seventy Bio's Q1 2024 performance was solid, with Abecma revenues meeting expectations.
The company's strategic realignment towards Abecma aims for cost efficiency and growth.
Challenges lie in achieving breakeven by 2025 and sustaining Abecma's market position.
Opportunities exist for increased profitability, market expansion, and operational efficiency.

2Seventy Bio focuses on ABECMA, reports strong Q2 earnings

2Seventy Bio's Q2 performance reflects a strategic shift towards profitability and sustainable growth.
The company's strong financial results and cost-saving measures position it well for future success.
While challenges exist, opportunities in product focus and financial management pave the way for a promising future.
Overall, 2Seventy Bio's focus on ABECMA and profitability sets a positive trajectory for the company.

2Seventy Bio reports robust Q3 growth driven by ABECMA success

2Seventy Bio's Q3 2024 performance reflects a strong return to growth, driven by a focus on ABECMA and operational efficiency.
While challenges such as market dynamics and cost optimization persist, the company's strategic strengths and growth opportunities position it well for the future.
With a positive market response to ABECMA and a commitment to expansion, 2Seventy Bio is poised to capitalize on its strengths and navigate challenges effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

2seventy Bio, Inc. operates as cell and gene therapy company. It concentrates on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.

2seventy bio, Inc. (TSVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's What You Should Know

NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT

2seventy bio, Inc. (NASDAQ:TSVT ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Morgan Shields – Corporate Communications Chip Baird – Chief Executive Officer Vicki Eatwell – Chief Financial Officer Conference Call Participants Samantha Semenkow – Citi Daina Graybosch – Leerink Partners Operator Good day and thank you for standing by. Welcome to the 2seventy bio Third Quarter 2024 Earnings Conference Call.

2seventy bio, Inc. (TSVT) Q3 2024 Earnings Call Transcript

2seventy bio, Inc. (TSVT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $1 per share a year ago.

2seventy bio, Inc. (TSVT) Reports Q3 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the third quarter ended September 30, 2024. “We are very pleased to report 42% sequential growth in quarterly Abecma sales, which was part of a continued expansion of the CAR-T class into earlier lines for multiple myeloma. When combined with the significant progress our team has made in streamlining our cost structure, 2seventy continues to make meaningful progress o.

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the financial results conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a un.

2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference

NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 2seventy bio, Inc. ("2seventy bio" or "the Company") (NASDAQ:TSVT). Investors who purchased 2seventy bio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TSVT.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against 2seventy bio, Inc. (TSVT) And Encourages Shareholders to Reach Out

NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 2seventy bio, Inc. ("2seventy bio" or "the Company") (NASDAQ:TSVT). Investors who purchased 2seventy bio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TSVT.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against 2seventy bio, Inc. (TSVT) and Encourages Shareholders to Learn More About the Investigation

NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a press release on September 25, 2024, announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant.

2seventy bio, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by 2seventy bio, Inc. (TSVT)

NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 2seventy bio, Inc. (“2seventy bio” or “the Company”) (NASDAQ: TSVT). Investors who purchased 2seventy bio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TSVT.

TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 2seventy bio, Inc. ("2seventy bio" or "the Company") (NASDAQ:TSVT). Investors who purchased 2seventy bio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TSVT.

Bronstein, Gewirtz & Grossman, LLC Is Investigating 2seventy bio, Inc. (TSVT) And Encourages Investors to Connect

NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a press release on September 25, 2024, announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant.

Did 2seventy bio, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- TSVT

NEW YORK, NY / ACCESSWIRE / October 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 2seventy bio, Inc. ("2seventy bio" or "the Company") (NASDAQ:TSVT). Investors who purchased 2seventy bio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TSVT.

Bronstein, Gewirtz & Grossman, LLC Encourages 2seventy bio, Inc. (TSVT) Stockholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESSWIRE / October 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a press release on September 25, 2024, announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant.

TSVT ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on Your 2seventy bio, Inc. investment

NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 2seventy bio, Inc. ("2seventy bio" or "the Company") (NASDAQ:TSVT). Investors who purchased 2seventy bio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TSVT.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against 2seventy bio, Inc. (TSVT) And Encourages Stockholders to Reach Out

NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a press release on September 25, 2024, announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant.

TSVT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of 2seventy bio, Inc. Shareholders Who Lost Money

NEW YORK, NY / ACCESSWIRE / October 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 2seventy bio, Inc. ("2seventy bio" or "the Company") (NASDAQ:TSVT). Investors who purchased 2seventy bio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TSVT.

Bronstein, Gewirtz & Grossman, LLC Is Investigating 2seventy bio, Inc. (TSVT) And Encourages Stockholders to Connect

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a press release on September 25, 2024, announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant.

An Investigation Has Commenced on Behalf of 2seventy bio, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your TSVT Losses

NEW YORK, NY / ACCESSWIRE / September 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a press release on September 25, 2024, announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant.

ATTENTION TSVT SHAREHOLDERS: Investors who lost money on 2seventy bio, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

NEW YORK, NY / ACCESSWIRE / September 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a press release on September 25, 2024, announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant.

2seventy bio, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - TSVT

Did 2seventy bio, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - TSVT

NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a press release on September 25, 2024, announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by 2seventy bio, Inc. (TSVT)

NEW YORK, NY / ACCESSWIRE / September 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a press release on September 25, 2024, announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant.

TSVT ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by 2seventy bio, Inc.

Bristol-Myers

2seventy bio and partner BMY decide to stop enrollment in the late-stage study on Abecma due to growth in the newly diagnosed multiple myeloma treatment space.

TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study

2seventy bio, Inc TSVT and its partner Bristol Myers Squibb & Co BMY, will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study of Abecma (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone for newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant.

News for 2Seventy Bio Stock (TSVT)